BioLineRx (BLRX) Current Assets (2012 - 2025)

BioLineRx's Current Assets history runs 14 years deep, the most recent figure standing at $23.7 million for Q4 2025.

• In Q4 2025, Current Assets fell 12.63% year-over-year to $23.7 million; the TTM figure through Dec 2025 stood at $23.7 million (down 12.63% YoY), while the FY2025 annual figure was $23.7 million, down 12.63% from the prior year.
• Current Assets was $23.7 million for Q4 2025 at BioLineRx, down from $28.5 million in the prior quarter.
• In the past five years, Current Assets ranged from a high of $67.1 million in Q2 2021 to a low of $23.7 million in Q4 2025.
• Historically, Current Assets has averaged $43.6 million across 5 years, with a median of $44.2 million in 2022.
• The sharpest annual moves came in 2021 and 2023: Current Assets surged 193.36% in 2021, then plunged 50.29% in 2023.
• A 5-year view of Current Assets shows it stood at $57.4 million in 2021, then slipped by 9.41% to $52.0 million in 2022, then dropped by 9.27% to $47.2 million in 2023, then tumbled by 42.56% to $27.1 million in 2024, then decreased by 12.63% to $23.7 million in 2025.
• The last three Current Assets figures came in at $23.7 million (Q4 2025), $28.5 million (Q3 2025), and $31.9 million (Q2 2025), per Business Quant data.